AKT1 and renal fibrosis: In general, Schisandrin B has shown various benefits in different organs and diseases, such as osteoarthritis, renal fibrosis, and myocardial ischemia (Ran et al., 2018; Zhao et al., 2018; Cao et al., 2019), and it has been reported to regulate several signaling pathways, including NF-κB, MAPK, PI3K/AKT, and Nrf2/HO-1 pathways (Zhu et al., 2017; Feng et al., 2018; Zhao et al., 2018; You et al., 2019).